abstract |
Use of a product that (i) antagonises the binding of respiratory syncytial virus (RSV) G-protein to annexin II or to L-selectin, or (ii) causes a decrease in cell surface levels of annexin II or L-selectin, in the manufacture of a medicament for use in preventing or treating infection by RSV. |